Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TEVA
TEVA logo

TEVA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
35.470
Open
34.790
VWAP
35.10
Vol
16.85M
Mkt Cap
41.13B
Low
34.520
Amount
591.59M
EV/EBITDA(TTM)
10.36
Total Shares
1.16B
EV
53.59B
EV/OCF(TTM)
31.27
P/S(TTM)
2.35
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Show More

Events Timeline

(ET)
2026-05-27
07:10:00
Teva Pharmaceuticals Commits to Veeva Vault CRM Globally
select
2026-05-21 (ET)
2026-05-21
12:40:00
Teva Pharmaceuticals Submits Long-Acting Olanzapine Application
select

News

NASDAQ.COM
9.0
05-22NASDAQ.COM
Teva and Medincell Submit Drug Application for Schizophrenia Treatment
  • Drug Application Progress: Teva Pharmaceuticals International GmbH and Medincell announced that the European Medicines Agency has accepted their Marketing Authorization Application for the long-acting injectable olanzapine (TEV-'749), marking a significant advancement in the treatment of schizophrenia in adults.
  • Technological Innovation: TEV-'749 utilizes Medincell's proprietary SteadyTeq copolymer technology, which enables controlled, steady, and prolonged release of olanzapine, expected to significantly enhance patient adherence and treatment outcomes.
  • Clinical Support: The submission is backed by an extensive clinical development program, including the Phase 3 SOLARIS study, indicating that the drug has demonstrated good safety and efficacy in clinical trials.
  • Market Dynamics: Although TEV-'749 has not yet been approved by any regulatory authority worldwide, Medincell's shares were trading at 26.62 euros, down 1.19% at the last close, reflecting market caution regarding the drug's future prospects.
Newsfilter
2.0
05-21Newsfilter
Teva Launches Long-Acting Injectable TEV-749 for Schizophrenia
  • Regulatory Approval: Teva and Medincell announced that the European Medicines Agency has accepted the Marketing Authorization Application for TEV-749, designed to provide a long-acting treatment for schizophrenia every four weeks, addressing a significant gap in current treatment options and expected to greatly enhance patient adherence.
  • Clinical Research Backing: The application for TEV-749 is supported by an extensive clinical development program, including the Phase 3 SOLARIS study, which demonstrated efficacy and safety profiles consistent with oral olanzapine, indicating its potential to transform schizophrenia treatment in real-world settings.
  • Strong Market Demand: With schizophrenia affecting 0.3% to 1.5% of the population in Europe, patients often face challenges such as social isolation and reduced quality of life; the introduction of TEV-749 is expected to provide a more convenient treatment option, thereby improving their quality of life and social functioning.
  • Strategic Growth Focus: As Teva advances TEV-749, it emphasizes its
seekingalpha
8.5
05-18seekingalpha
Mark Cuban to Join Trump for Generic Drug Announcement
  • Pharmacy Collaboration: Mark Cuban's Cost Plus Drugs online pharmacy is set to collaborate with Trump's TrumpRx website to offer a wide range of generic medicines, which is expected to significantly reduce drug costs for consumers, particularly those without insurance.
  • Significant Price Advantage: Cost Plus Drugs sells both branded and generic drugs at discounts below insurance-covered prices, with Cuban stating that a 30-day supply of the generic drug Eliquis costs $345, showcasing its competitive edge in the pharmaceutical market.
  • Positive Market Response: This initiative may generate widespread attention in the pharmaceutical industry, especially regarding drug price transparency and affordability, potentially driving increased consumer demand for generics.
  • Industry-Wide Impact: Cuban's involvement not only enhances the visibility of Cost Plus Drugs but may also compel other pharmaceutical companies to reconsider their pricing strategies, thereby triggering price competition across the industry.
Newsfilter
6.0
05-18Newsfilter
Teva Pharmaceutical's Credit Rating Upgraded to Investment Grade
  • Credit Rating Upgrade: Fitch has upgraded Teva's corporate credit rating from BB+ to investment grade BBB-, marking a significant endorsement of the company's successful transformation and growth strategy, which enhances market confidence in its financial flexibility.
  • Debt Rating Improvement: Teva's senior unsecured debt and credit facilities ratings have also been raised to BBB-, reflecting the company's sustained progress in financial robustness and cash flow generation, which is expected to further support its operating margin improvement.
  • Innovation-Driven Growth: Fitch anticipates continued growth in Teva's innovative revenues, primarily driven by products like AUSTEDO® and AJOVY®, along with upcoming launches such as olanzapine LAI, highlighting the company's strategic shift towards a higher-margin product portfolio.
  • Enhanced Financial Flexibility: The ongoing cash flow generation and balance sheet strengthening will enhance Teva's financial flexibility, providing support for future investments and product development, thereby solidifying its leadership position in the biopharmaceutical sector.
Fool
7.5
05-15Fool
Teva Pharmaceuticals Transforms, Poised for Growth
  • Debt Reduction: Teva Pharmaceuticals has successfully reduced over $5 billion in debt over recent years, alleviating legal liabilities related to the opioid crisis, thereby improving its financial health and boosting market confidence.
  • Branded Drug Growth: Despite a 1% decline in overall sales to $4 billion, the branded drug segment performed strongly, with Austedo generating $578 million in revenue, a 41% year-over-year increase, highlighting the significance of branded products in the company's revenue stream.
  • Future Potential: Teva's biosimilars segment is expected to deliver $800 million in revenue by 2027, further stabilizing and growing the company's legacy business, enhancing its competitive position in the market.
  • Drug Pipeline Outlook: Teva plans to launch multiple new drugs between 2026 and 2030, potentially adding up to $7 billion in annual sales, showcasing the company's strong potential in drug development and market appeal.
Fool
9.5
05-14Fool
Teva Pharmaceutical Stock Doubles, Analysts Remain Optimistic
  • Stock Price Surge: Teva Pharmaceutical's stock has soared over 100% in the past 12 months, reflecting strong market confidence in its recovery, with analysts generally optimistic about its future performance.
  • Analyst Ratings Positive: In a survey by S&P Global, 12 out of 13 analysts rated Teva as a 'buy' or 'strong buy', indicating recognition of its potential 11% upside in the market.
  • Significant Sales Growth: Teva's Austedo drug saw first-quarter sales jump 41% year-over-year to $578 million, driving overall performance improvements and further boosting market confidence.
  • Improved Financial Health: As of March 31, 2026, Teva's financial leverage dropped to 67%, and the company expects to realize approximately $470 million in net savings from transformation initiatives, demonstrating proactive efforts in cost-cutting and financial health improvement.
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
Wall Street analysts forecast TEVA stock price to rise
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
29.00
Averages
35.71
High
40.00
Current: 0.000
sliders
Low
29.00
Averages
35.71
High
40.00
Barclays
NULL
to
Overweight
maintain
$38 -> $40
AI Analysis
2026-05-06
Reason
Barclays
Price Target
$38 -> $40
AI Analysis
2026-05-06
maintain
NULL
to
Overweight
Reason
Barclays raised the firm's price target on Teva to $40 from $38 and keeps an Overweight rating on the shares.
Goldman Sachs
Buy
maintain
$45 -> $50
2026-04-30
Reason
Goldman Sachs
Price Target
$45 -> $50
2026-04-30
maintain
Buy
Reason
Goldman Sachs raised the firm's price target on Teva to $50 from $45 and keeps a Buy rating on the shares. Teva delivered encouraging results, with strong outperformance in its branded business and additional support from a deal that appears consistent with its stated strategy of pursuing clinically de-risked, mid-sized opportunities with commercial synergies, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TEVA
Unlock Now

Valuation Metrics

The current forward P/E ratio for Teva Pharmaceutical Industries Limited.. (TEVA.N) is 12.69, compared to its 5-year average forward P/E of 5.20. For a more detailed relative valuation and DCF analysis to assess Teva Pharmaceutical Industries Limited..'s fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
5.20
Current PE
12.69
Overvalued PE
7.58
Undervalued PE
2.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
7.49
Current EV/EBITDA
12.40
Overvalued EV/EBITDA
9.71
Undervalued EV/EBITDA
5.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.00
Current PS
2.33
Overvalued PS
1.48
Undervalued PS
0.52

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

xene swing trade
Intellectia · 61 candidates
Sector: Healthcare, Healthcare Services & EquipmentIndustry: Biotechnology & Medical Research, PharmaceuticalsRsi Category: moderateRelative Vol: >= 1.20List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA60Is Optionable: TrueSupport Resistance Relationship: PriceBreakResistance, PriceAroundResistance
Ticker
Name
Market Cap$
top bottom
AVBP logo
AVBP
ArriVent BioPharma Inc
1.41B
SCLX logo
SCLX
Scilex Holding Co
75.57M
MGTX logo
MGTX
MeiraGTx Holdings PLC
986.29M
TEVA logo
TEVA
Teva Pharmaceutical Industries Limited..
41.13B
GILD logo
GILD
Gilead Sciences, Inc
166.90B
RVMD logo
RVMD
Revolution Medicines Inc
33.48B
si quiero con acciones de estados unidos
Intellectia · 30 candidates
Market Cap: >= 10.00BRegion: USPrice: $10.00 - $60.00Analyst Consensus: Strong BuyPe Ttm: 5 - 30List Exchange: XNYS, XNAS
Ticker
Name
Market Cap$
top bottom
BAC logo
BAC
Bank of America Corp
384.66B
SLB logo
SLB
SLB NV
78.36B
NU logo
NU
Nu Holdings Ltd.
73.40B
B logo
B
Barrick Mining Corp
71.97B
MFC logo
MFC
Manulife Financial Corp
64.64B
BKR logo
BKR
Baker Hughes Co
58.68B
top 10 crypto gainers today
Intellectia · 512 candidates
Price Change Pct 24h: >= $0.00
Ticker
Name
Market Cap$
top bottom
ZEX logo
ZEX
Zeta
6.11M
MDT logo
MDT
Measurable Data Token
5.68M
AKE logo
AKE
AKEDO
9.28M
KIN logo
KIN
Kindred Labs
1.88M
UNITE logo
UNITE
Unite
106.81K
CHILLGUY logo
CHILLGUY
Just a chill guy
11.99M
no which two coins under .01
Intellectia · 347 candidates
Turnover 24h: >= 0Price: $0.00 - $0.01Relative Vol: >= 0Dollar Volume 24h: >= 0
Ticker
Name
Market Cap$
top bottom
PEPE logo
PEPE
Pepe
1.65B
G logo
G
Gravity
56.10M
PUMP logo
PUMP
Pump.fun
716.00M
BONK logo
BONK
Bonk
579.97M
PENGU logo
PENGU
Pudgy Penguins
498.58M
SHIB logo
SHIB
Shiba Inu
3.66B
What stoke should I buy ?
Intellectia · 60 candidates
Market Cap: >= 30.00BQuarter Revenue Yoy Growth: >= 10.0%Return On Equity: >= 15.0%Moving Average Relationship: PriceAboveMA200Monthly Average Dollar Volume: >= 1,500,000
Ticker
Name
Market Cap$
top bottom
LITE logo
LITE
Lumentum Holdings Inc
42.87B
WDC logo
WDC
Western Digital Corp
96.32B
MU logo
MU
Micron Technology Inc
449.96B
FIX logo
FIX
Comfort Systems USA Inc
47.19B
AU logo
AU
Anglogold Ashanti PLC
53.60B
KGC logo
KGC
Kinross Gold Corp
40.90B
stocks to buy tomorrow
Intellectia · 358 candidates
Market Cap: >= 5.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Day Rise Prob: >= 55Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
TER logo
TER
Teradyne Inc
43.25B
DINO logo
DINO
HF Sinclair Corp
10.32B
MT logo
MT
ArcelorMittal SA
44.06B
AROC logo
AROC
Archrock Inc
5.35B
EXAS logo
EXAS
Exact Sciences Corp
19.49B
AEP logo
AEP
American Electric Power Company Inc
64.75B
show me large cap stocks with key reversal
Intellectia · 44 candidates
Market Cap: >= 10.00BNew High Low: 52w_High, 52w_Low, 20_High, 20_LowCandlestick Pattern: UpperShadow, LowerShadow
Ticker
Name
Market Cap$
top bottom
WMT logo
WMT
Walmart Inc
949.57B
CSCO logo
CSCO
Cisco Systems Inc
309.45B
AZN logo
AZN
AstraZeneca PLC
287.64B
MRK logo
MRK
Merck & Co Inc
273.69B
TXN logo
TXN
Texas Instruments Inc
193.96B
MFG logo
MFG
Mizuho Financial Group Inc
106.59B
stocks currently in bullish trend
Intellectia · 39 candidates
Market Cap: >= 10.00BList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Quarter Price Change Pct: >= $50.00Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
MU logo
MU
Micron Technology Inc
439.39B
NEM logo
NEM
Newmont Corporation
140.53B
CVNA logo
CVNA
Carvana Co
104.69B
FCX logo
FCX
Freeport-McMoRan Inc
89.29B
B logo
B
Barrick Mining Corp
86.76B
WDC logo
WDC
Western Digital Corp
86.45B
give me your top pick
Intellectia · 10 candidates
Market Cap: >= 10.00BMarket Cap Category: mega, largeAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Month Predict Return: >= 15.0%
Ticker
Name
Market Cap$
top bottom
ROST logo
ROST
Ross Stores Inc
60.49B
NI logo
NI
NiSource Inc
20.77B
APG logo
APG
APi Group Corp
18.28B
META logo
META
Meta Platforms Inc
1.63T
EME logo
EME
EMCOR Group Inc
31.47B
PEN logo
PEN
Penumbra Inc
14.07B

Whales Holding TEVA

P
Polar Capital Holdings Plc
Holding
TEVA
+36.25%
3M Return
M
More Investment House Ltd.
Holding
TEVA
+23.24%
3M Return
M
Meitav Investment House Ltd
Holding
TEVA
+22.77%
3M Return
C
Clal Financial Management Ltd
Holding
TEVA
+22.41%
3M Return
H
Harel Insurance Investments & Financial Services Ltd
Holding
TEVA
+20.66%
3M Return
C
Castle Hook Partners LP
Holding
TEVA
+19.49%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Teva Pharmaceutical Industries Limited.. (TEVA) stock price today?

The current price of TEVA is 35.32 USD — it has increased 2.32

What is Teva Pharmaceutical Industries Limited.. (TEVA)'s business?

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

What is the price predicton of TEVA Stock?

Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Teva Pharmaceutical Industries Limited.. (TEVA)'s revenue for the last quarter?

Teva Pharmaceutical Industries Limited.. revenue for the last quarter amounts to 3.97B USD, increased 1.33

What is Teva Pharmaceutical Industries Limited.. (TEVA)'s earnings per share (EPS) for the last quarter?

Teva Pharmaceutical Industries Limited... EPS for the last quarter amounts to 0.31 USD, increased 63.16

How many employees does Teva Pharmaceutical Industries Limited.. (TEVA). have?

Teva Pharmaceutical Industries Limited.. (TEVA) has 31173 emplpoyees as of May 31 2026.

What is Teva Pharmaceutical Industries Limited.. (TEVA) market cap?

Today TEVA has the market capitalization of 41.13B USD.